Urbán, L.; Dóczi, R.; Vodicska, B.; Kormos, D.; Tóth, L.; Takács, I.; Várkondi, E.; Tihanyi, D.; Lakatos, D.; Dirner, A.;
et al. Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC. J. Pers. Med. 2020, 10, 107.
https://doi.org/10.3390/jpm10030107
AMA Style
Urbán L, Dóczi R, Vodicska B, Kormos D, Tóth L, Takács I, Várkondi E, Tihanyi D, Lakatos D, Dirner A,
et al. Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC. Journal of Personalized Medicine. 2020; 10(3):107.
https://doi.org/10.3390/jpm10030107
Chicago/Turabian Style
Urbán, László, Róbert Dóczi, Barbara Vodicska, Dóra Kormos, László Tóth, István Takács, Edit Várkondi, Dóra Tihanyi, Dóra Lakatos, Anna Dirner,
and et al. 2020. "Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC" Journal of Personalized Medicine 10, no. 3: 107.
https://doi.org/10.3390/jpm10030107
APA Style
Urbán, L., Dóczi, R., Vodicska, B., Kormos, D., Tóth, L., Takács, I., Várkondi, E., Tihanyi, D., Lakatos, D., Dirner, A., Vályi-Nagy, I., & Peták, I.
(2020). Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC. Journal of Personalized Medicine, 10(3), 107.
https://doi.org/10.3390/jpm10030107